

CTVD MEMBERSHIP UPDATE

For those of you who have been with us since the inception of CTVD, thank you for your continued involvement. For those of you who are new to CTVD, welcome! We now have 67 member institutions... and we are still growing.

4TH ANNUAL CTVD MEETING

The 5th Annual CTVD Meeting will be held at the Gates Foundation in Seattle, WA June 18-20, 2019. Research communities will convene on June 18 and the general meeting will be held June 19 and 20. Stay tuned for program details as we get closer to June. To view the presentations from the 2018 annual meeting, as well as our junior investigator abstracts, please visit <https://portal.ctvd.co/ctvdmeetings/Pages/Seattle18.aspx>

CTVD PORTAL

Have you missed previously recorded CTVD webinars or meetings? Want to view documents from your Research Community? Access to the secure portal is available to CTVD members whose institution has signed the DMSA (data and materials sharing agreement). Visit the CTVD Portal, located in the upper right hand corner of the CTVD home page, <https://www.ctvd.co>, to access all this information and more. Forgot your logon? Contact Ksenia Koon (kkoon@ctvd.co), CTVD Manager, for help.

UPCOMING VIRTUAL FORUMS

The CTVD holds monthly webinars aimed at keeping our members informed of exciting advances in the field. If you have ideas for topics/speakers for upcoming virtual forums, please send them our way!

Please also make more junior colleagues in your group aware of the webinars, if you think these would be useful.

The next CTVD webinar will be held **October 18, 2018**.

Date: Thursday, October 18, 2018
Time: 8:00 am PDT/ 11:00 am EDT/ 15h00 UTC/ 4:00 pm BST London/ 5:00 pm CEST Geneva/ 5:00 pm SAST Johannesburg/ 10:00 pm ICT Bangkok
Presenter: Olivier Van Der Meeren, MD; Director, Senior Clinical R&D Lead GSK Vaccines
Presentation Title: A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine against Pulmonary Tuberculosis Disease in Adults with Latent Mycobacterium tuberculosis Infection
Abstract: An effective tuberculosis (TB) vaccine is urgently needed to support the End TB Strategy to reduce the number of new TB cases by 80% by 2030. M72/AS01E candidate vaccine is an adjuvanted recombinant fusion protein derived from Mycobacterium tuberculosis Mtb32A and Mtb39A proteins. We conducted a randomized, double-blind, placebo-controlled phase 2b trial (NCT01755598) in Southern and Eastern Africa to assess M72/AS01E's efficacy against bacteriologically-confirmed pulmonary TB disease in HIV-seronegative (HIV-) adults aged 18-50 years infected with Mtb (defined by a positive IFN- γ release assay). Participants were randomized 1:1 to receive M72/AS01E or placebo at day D0 and D30. The results of the primary analysis of safety and efficacy will be discussed.



To join this one hour online event on **October 18th**:

1. Go to: [WebEx Meeting](#)
2. Enter your first name, last name, and email address
3. Enter the event password: **CTVD123**

If you have any problems joining, please send an email to brian@regenworks.com
(Phone: 425.999.2420)

Additional Information

Presenter's Bio

Dr. Olivier Van Der Meeren graduated as a Medical Doctor from Brussels University in 1997. Since then he has worked as a scientist in Roche, Pfizer and GSK. His work focused on the treatment and prevention of infectious diseases. He has been leading the clinical development of vaccines for the past 11 years at GSK, and currently works on the TB and HIV vaccines. He authored more than 32 peer-reviewed publications and is a reviewer for several journals publishing vaccine studies.

To view the most recent webinar, visit CTVD portal, located in the upper right hand corner of the CTVD home page, at <https://www.ctvd.co>

RESEARCH COMMUNITY UPDATE

CTVD currently has seven research communities. The BMGF team elects two leaders to each community, and allow these leaders complete freedom to arrange their community's composition, meeting schedules and agendas, as long as they address the primary brief: What are the research priorities in your specific area that absolutely have to be addressed if we wish to arrive at a new, better TB vaccine. We, at the Gates Foundation, champion these research communities and aim to facilitate funding of priorities through discussions with other funders.

If you have questions about any of the research communities, please contact one of the co-chairs of the group:

Aerosol and Mucosal Vaccination: Helen McShane, Rajko Reljic

B-cells and Antibodies: Babak Javid, Simone Joosten

Conventional T cells: Delia Goletti, Joythi Rengaragan

Donor-Unrestricted T Cells: Tom Ottenhoff, Chetan Seshadri

Innate Immunity: Mihai Natea, Shabaana Khader

Non-Human Primates: Trisha Darrah, Ann Rawkins

Whole Cell TB Vaccines: Roland Brosch, Eric Rubin

EARLY CAREER SCIENTIST AWARD

We believe acknowledgment of contributions of junior scientist is an important activity toward CTVD's overall aim, which is to foster collaboration and cooperation toward innovation for TB vaccine discovery and development. The CTVD Early Career Scientist Award recognizes the efforts of early career scientists who have made significant contributions in TB host-pathogen biology, immunology, and vaccinology. Multiple awards are given each year; we feature awardees' contributions on the websites and provide each with a grant to attend any TB-related conference: registration and travel (air flight, lodging, and meals) are covered.

All nominations must be submitted electronically via the link below. Nominations will not be accepted by email or by post. Please submit your nominations today!

<https://www.ctvd.co/Pages/EarlyCareerScientistAward.aspx>

VISITING SCIENTIST PROGRAM

The Visiting Scientist Program also addresses CTVD's overall aim, by enabling scientists from different CTVD member institutions to visit each other for exchange of information and techniques. Travel expenses (air flight, lodging, and meals) for up to three weeks is covered.

Please visit <https://www.ctvd.co/Pages/VisitingScientistProgram.aspx> for more information and to apply!

CTVD ADVISORY COUNCIL

The CTVD Advisory Council is comprised of the co-chairs from each of the seven research communities, plus a representative from TBVI, Gates MRI and IAVI. The Advisory Council meets semi-annually and provides input into CTVD direction.

GH-VAP

The Global Health Vaccine Accelerator Platform (GH-VAP) program provides investigators with access to several specialized research platforms to accelerate vaccine discovery and translation across infectious disease areas. To learn more, visit GH-VAP at <https://www.ghvap.org>

GTBVP

In a project initiated by the Global TB Vaccine Partnership (GTBVP) and funded by the foundation, TBVI and Aeras have developed a fantastic, interactive web tool describing stages of development of new vaccine candidates. The web tool also suggests specific stage gate criteria appropriate for TB vaccines. The output is the result of wide stakeholder consultation. Please refer to the 'The TB Vaccine Development Pathway' at <https://www.tbvacpathway.org/>

PUBLICATIONS OF INTEREST

[Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis](#)

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitie MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khaton Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.
N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1803484.

[Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination](#)

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M, C-040-404 Study Team.
N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

Do you have an article that you think the CTVD community would enjoy reading? If so, please let us know. We welcome your contributions of publications of interest for upcoming newsletters and our website.

FEEDBACK

If you have questions or comments, please contact the CTVD program manager at kkoon@ctvd.co

[CTVD.co](#) | [CTVD Portal](#) | [Support](#)

© 2018 - Collaboration for TB Vaccine Discovery

content and editing by K. Koon

layout and design by B. Sanders

Unsubscribe to CTVD announcements, [click here](#)